 Aminopyridines
"Aminopyridines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Pyridines substituted in any position with an amino group. May be hydrogenated, but must retain at least one double bond.
| Descriptor ID |
D000631
|
| MeSH Number(s) |
D02.092.080 D03.383.725.050
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Aminopyridines".
Below are MeSH descriptors whose meaning is more specific than "Aminopyridines".
This graph shows the total number of publications written about "Aminopyridines" by people in this website by year, and whether "Aminopyridines" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2008 | 2 | 3 | 5 | | 2009 | 1 | 2 | 3 | | 2010 | 2 | 1 | 3 | | 2012 | 1 | 0 | 1 | | 2013 | 0 | 1 | 1 | | 2015 | 2 | 3 | 5 | | 2016 | 0 | 1 | 1 | | 2017 | 4 | 0 | 4 | | 2018 | 6 | 5 | 11 | | 2019 | 4 | 4 | 8 | | 2020 | 4 | 4 | 8 | | 2021 | 3 | 7 | 10 | | 2022 | 0 | 6 | 6 | | 2023 | 0 | 3 | 3 | | 2024 | 1 | 3 | 4 | | 2025 | 2 | 4 | 6 | | 2026 | 1 | 5 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Aminopyridines" by people in Profiles.
-
Zemanick ET, Graeber SY, Castellani C, Cutting GR, Fajac I, Konstan MW, Linnemann RW, McKone EF, Metcalf A, Solomon GM, Taylor-Cousar JL, Mayer-Hamblett N, Mall MA. The role of sweat chloride in determining CFTR protein restoration in people with cystic fibrosis. Lancet Respir Med. 2026 Aug; 14(8):704-716.
-
Da Cruz RS, Teague HL, Ramos-Benitez MJ, Malavez-Cajigas SJ, Williams T, Miao R, Tian X, Lin G, Busse LW, Khan A, Moskowitz A, Hager DN, Rice TW, Ginde AA, Iovine NM, Chen P, Safdar B, Gibbs KW, Javaheri A, de Wit M, Harkins M, Hudock K, Merck LH, Barksdale A, Sturek JM, Schrager H, Shapiro NI, Lanspa M, Harris E, Sellers S, Goodwin AJ, Tidswell MA, Filbin MR, Shotwell MS, Semler MW, Self WH, Collins SP, Strich JR. Impact of Fostamatinib on Inflammatory Biomarkers in Hospitalized Patients With COVID-19. Crit Care Explor. 2026 Jul 01; 8(7):e1405.
-
Benedetto A, Boguniewicz M, Fonacier L, Silverberg J, Abuabara K, Ong PY. Atopic dermatitis Yardstick: A new era of topical and systemic treatments. Ann Allergy Asthma Immunol. 2026 Aug; 137(2):252-265.
-
Razak A, Mahipal A, Diamond JR, Ribas A, Berlin JD, Azmi AS, Mark T, Walker CJ, Chai Y, Kashyap T, Gudi G, Naing A. First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies. Target Oncol. 2026 Mar; 21(2):187-198.
-
Christenson JL, Spoelstra NS, Williams MM, Logan LL, O'Neill KI, Orlicky DJ, Baker NT, Wagner JA, Staley AW, Van Bokhoven A, Goodspeed A, Kuo LW, Crump LS, Diamond JR, Richer JK. Metastasis-Associated Wound Repair Promotes Reciprocal Lung Epithelium Activation and Breast Cancer Metastatic Outgrowth. Cancer Res Commun. 2026 04 01; 6(4):750-768.
-
Eichenfield LF, Gonzalez ME, Boguniewicz M, Funk T, Hebert AA, Prajapati VH, Kindred C, Serrao R, Swanson L, Krupa D, Snyder S, Seal MS, Hanna D, Burnett P, Berk DR. Long-Term Safety and Efficacy of Once-Daily and Proactive Twice-Weekly Roflumilast Cream 0.05% for Mild-to-Moderate Atopic Dermatitis in Children Aged 2-5?Years From a 52-Week, Phase 3 Trial (INTEGUMENT-OLE). Pediatr Dermatol. 2026 May-Jun; 43(3):642-649.
-
Tomita Y, Link G, Ge Y, Gold ERH, Racanelli A, Cardona HJ, Romero M, Gadd S, Watanabe J, Uchida E, Hashizume R, Takata N, Pinero G, Hambardzumyan D, Spasojevic I, Hu G, Hennika T, Brat DJ, Green AL, Becher OJ. Effects of combination therapy of a CDK4/6 and MEK inhibitor in diffuse midline glioma preclinical models. PLoS One. 2025; 20(12):e0323235.
-
Waliany S, Roy SG, Pecci F, Weber UM, Sun F, Arter Z, Lomibao M, Alessi JV, Nishino M, Luo F, Repetto M, Falcon C, Do A, Peterson J, Liang J, Liu A, Nagasaka M, Ricciuti B, Drilon A, Ou SI, Neal JW, Patil T, Awad M, Yeap BY, Digumarthy SR, Lin JJ. Efficacy and Safety of Continuing Next-Generation ALK TKIs With Chemotherapy for Advanced ALK-Positive NSCLC: A Multicenter Retrospective Study. J Natl Compr Canc Netw. 2025 Nov 19; 23(12):522-530.
-
Baird RD, Bermejo de Las Heras B, Ruiz-Borrego M, Vaklavas C, Moreno I, Oliveira M, Armstrong A, Turner N, Incorvati J, Twelves C, Ciruelos E, Hamilton E, Patel MR, Kabos P, Ciardullo C, Klinowska T, Lindemann JPO, Mathewson AM, Morrow CJ, Sykes A, Yang J, Zhang B, Victoria I. Camizestrant in Combination with Three Globally Approved CDK4/6 Inhibitors in Women with ER+, HER2- Advanced Breast Cancer: Results from SERENA-1. Clin Cancer Res. 2025 Oct 15; 31(20):4244-4254.
-
Bdaiwi AS, Roach DJ, West ME, Willmering MM, Daou AW, Hossain MM, Kramer EL, Amin R, Walkup LL, Cleveland ZI, Woods JC. Longitudinal Monitoring of Lumacaftor/Ivacaftor Response in Young Children with Cystic Fibrosis Lung Disease Using 129Xe MRI. Acad Radiol. 2025 Oct; 32(10):6238-6249.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|